CD274 and neoplasm: We selected cefepime among the identified PDDs on the basis of its relative efficacy in tumor PDL1 depletion, its FDA approval, its relative safety, its low cost, and the existence of many commercially available β-lactam molecules for the initial structure–activity-relationship studies.